Amgen Inc

NASDAQ:AMGNUnited States

Today

Show headlines and story abstract

• TEPEZZA(R) (TEPROTUMUMAB) RECEIVES APPROVAL IN JAPAN FOR THE TREATMENT OF ACTIVE THYROID EYE DISEASE, from 25 minutes ago by PR Newswire

  25 minutes ago by PR Newswire
  Companies Mentioned: AMGN

  Amgen (NASDAQ:AMGN) today announced TEPEZZA(R) (JAN: Teprotumumab (Genetical Recombination)) has been approved for the treatment of active or high clinical activity score (CAS) Thyroid Eye Disease (TED)by Japan's Ministry of Health, Labour and Welfare (MHLW).

• TEPEZZA(R) (TEPROTUMUMAB) RECEIVES APPROVAL IN JAPAN FOR THE TREATMENT OF ACTIVE THYROID EYE DISEASE, from 25 minutes ago by Dow Jones

  25 minutes ago by Dow Jones
  Companies Mentioned: AMGN
  
  This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla(R) (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on our acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.
  

• US Equity Indexes Rise as Sliding Consumer Confidence Undermines Bowman's Call for Policy Caution, from 2 hours ago by MT Newswires

  2 hours ago by MT Newswires
  Companies Mentioned: V, LVS, MAR, REGN, AMGN
  01:41 PM EDT, 09/24/2024 (MT Newswires) -- US equity indexes rose after consumer confidence fell the most in three years and a regional manufacturing gauge deteriorated, calling into question Federal Reserve Governor Michelle Bowman's stance favorin...